Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X about recent paper by Byoung Chul Cho et al., published in Journal of Thoracic Oncology.
“Hot Off The Press.
Just published in JTO online, results of: The COCOON Trial
The very important supportive care randomized trial of: Enhanced versus standard prophylactic dermatologic management during treatment with Amivantamab/Lazertinib in patients with EGFR+ advanced NSCLC:
Significant reduction in dermatologic adverse events. COCOON enhanced prophylaxis is now a must and standard of care with the MARIPOSA regimen.”
Title: Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
Authors: Byoung Chul Cho, Weimin Li, Alexander I. Spira, Maxwell Sauder, Jill Feldman, Farastuk Bozorgmehr, Milena Mak, Janellen Smith, Pei Jye Voon, Baogang Liu, Panwen Tian, Jiunn-Liang Tan, Cheng-Ta Yang, Jin-Yuan Shih, Nuri Karadurmus, Juan Esteban Cundom, Glaucio Bertollo, Irfan Cicin, Jorge Nieva, Ana Laura Ortega-Granados, Pascale Tomasini, Danny Nguyen, Enriqueta Felip, Julia Schuchard, Sean P. Murphy, Bailey G. Anderson, Tonatiuh Romero, Yichuan Xia, Shubin Sheng, Joshua M. Bauml, Parthiv J. Mahadevia, Julian Kam, Mehregan Nematian-Samani, Jairo Simoes, Mark Wildgust, Nicolas Girard
More posts featuring Rami Manochakian on OncoDaily.